dc.date.accessioned |
2021-06-03T11:02:19Z |
|
dc.date.available |
2021-06-03T11:02:19Z |
|
dc.date.issued |
2021 |
|
dc.identifier.issn |
1473-0502 |
|
dc.identifier.uri |
https://www.doi.org/10.1016/j.transci.2020.102955 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12619/95455 |
|
dc.description |
Bu yayın 06.11.1981 tarihli ve 17506 sayılı Resmî Gazete’de yayımlanan 2547 sayılı Yükseköğretim Kanunu’nun 4/c, 12/c, 42/c ve 42/d maddelerine dayalı 12/12/2019 tarih, 543 sayılı ve 05 numaralı Üniversite Senato Kararı ile hazırlanan Sakarya Üniversitesi Açık Bilim ve Açık Akademik Arşiv Yönergesi gereğince açık akademik arşiv sistemine açık erişim olarak yüklenmiştir. |
|
dc.description |
Bu yayın 06.11.1981 tarihli ve 17506 sayılı Resmî Gazete’de yayımlanan 2547 sayılı Yükseköğretim Kanunu’nun 4/c, 12/c, 42/c ve 42/d maddelerine dayalı 12/12/2019 tarih, 543 sayılı ve 05 numaralı Üniversite Senato Kararı ile hazırlanan Sakarya Üniversitesi Açık Bilim ve Açık Akademik Arşiv Yönergesi gereğince açık akademik arşiv sistemine açık erişim olarak yüklenmiştir. |
|
dc.description.abstract |
Introduction: Passive antibody therapy has been used to immunize vulnerable people against infectious agents. In this study, we aim to investigate the efficacy of convalescent plasma (CP) in the treatment of severe and critically ill patients diagnosed with COVID-19. Method: The data of severe or critically ill COVID-19 patients who received anti-SARS-CoV-2 antibody-containing CP along with the antiviral treatment (n = 888) and an age-gender, comorbidity, and other COVID-19 treatments matched severe or critically ill COVID-19 patients at 1:1 ratio (n = 888) were analyzed retrospectively. Results: Duration in the intensive care unit (ICU), the rate of mechanical ventilation (MV) support and vasopressor support were lower in CP group compared with the control group (p = 0.001, p = 0.02, p = 0.001, respectively). The case fatality rate (CFR) was 24.7 % in the CP group, and it was 27.7 % in the control group. Administration of CP 20 days after the COVID-19 diagnosis or COVID-19 related symptoms were associated with a higher rate of MV support compared with the first 3 interval groups (?5 days, 6-10 days, 11-15 days) (p=0.001). Conclusion: CP therapy seems to be effective for a better course of COVID-19 in severe and critically ill patients. |
|
dc.language |
English |
|
dc.language.iso |
eng |
|
dc.publisher |
PERGAMON-ELSEVIER SCIENCE LTD |
|
dc.relation.isversionof |
10.1016/j.transci.2020.102955 |
|
dc.rights |
info:eu-repo/semantics/openAccess |
|
dc.subject |
SARS-CoV-2 |
|
dc.subject |
Convalescent plasma |
|
dc.subject |
COVID-19 |
|
dc.title |
Convalescent plasma therapy in patients with COVID-19 |
|
dc.type |
Article |
|
dc.contributor.authorID |
Erkurt, Mehmet Ali/0000-0002-3285-417X |
|
dc.contributor.authorID |
Basci, Semih/0000-0003-4304-9245 |
|
dc.contributor.authorID |
BASTURK, ABDULKADIR/0000-0003-1864-0316 |
|
dc.contributor.authorID |
celik, osman/0000-0003-2131-2866 |
|
dc.identifier.volume |
60 |
|
dc.relation.journal |
TRANSFUSION AND APHERESIS SCIENCE |
|
dc.identifier.issue |
1 |
|
dc.identifier.wos |
WOS:000639152200050 |
|
dc.identifier.doi |
10.1016/j.transci.2020.102955 |
|
dc.identifier.eissn |
1878-1683 |
|
dc.contributor.author |
Altuntas, Fevzi |
|
dc.contributor.author |
Ata, Naim |
|
dc.contributor.author |
Yigenoglu, Tugce Nur |
|
dc.contributor.author |
Basci, Semih |
|
dc.contributor.author |
Dal, Mehmet Sinan |
|
dc.contributor.author |
Korkmaz, Serdal |
|
dc.contributor.author |
Namdaroglu, Sinem |
|
dc.contributor.author |
Basturk, Abdulkadir |
|
dc.contributor.author |
Hacibekiroglu, Tuba |
|
dc.relation.publicationcategory |
Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı |
|
dc.identifier.pmıd |
33011076 |
|
dc.rights.openaccessdesignations |
Green Published, Bronze |
|